CYTOF — Altamira Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual cashflow statement for Altamira Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	C2021 December 31st	R2022 December 31st	R2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	20-F	20-F	20-F	20-F	20-F
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	fx Final	fx Final	Final	Final	Final
Net Income/Starting Line	-8.74	-18.7	-27.8	-4.31	-8.46
Depreciation
Non-Cash Items	3.24	3.42	13.9	-3.92	2.19
Discontinued Operations
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	0.32	0.196	4.7	-4.72	0.028
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities	-5.16	-15	-9.09	-12.8	-6.11
Capital Expenditures	-2.47	-3.64	-2.24	0	-0.103
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	0	-0.196	0.001	1.61	-0.012
Sale of Business
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-2.47	-3.83	-2.24	1.61	-0.115
Financing Cash Flow Items	-0.679	-0.176	-0.058	-1.04	-0.729
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	18.1	7.24	10.3	11.8	6.51
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	10.5	-11.2	-1.06	0.717	0.265